glp-1 inhibitors Comparing Ozempic, Wegovy and Other Drugs How GLP-1 Receptor Agonists Evolved
Description
Emerging research also explores its potential role in liver protection and metabolic health
Non-canonical activation mechanisms may exist and the ECD could play a different role assuming different conformations depending on the ligand 24
GLP-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution By Donnisa Edmonds, C2ST Intern, University of Chicago In 2021, the FDA announced that they had approved Wegovy, a GLP-1 receptor agonist, as a treatment for chronic weight management
The STEP 1 clinical trial, which investigated the efficacy of 2.4 mg semaglutide, included a substudy specifically analyzing body composition via dual-energy X-ray absorptiometry (DEXA) [1]
